🏛️ Verified NIH Record • Updated 2026-02-04

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (NCT03938987)

A Phase 1b/2 Multi-center, De-centralized, Dose Selection Study of Autologous CD19-directed Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: University of Alberta

🩺 Plain-English Summary (8th-Grade Level)

Autologous, unselected CD3+ lymphocytes collected from apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ).

Who can join: Review the eligibility criteria below.

Location: Foothills Medical Centre — Calgary, Alberta

Age range: 2 Years to 70 Years

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (6 Sites)

  • Foothills Medical Centre — Calgary, Alberta
  • Tom Baker Cancer Centre — Calgary, Alberta
  • Alberta Children's Hospital — Calgary, Alberta
  • Cross Cancer Institute — Edmonton, Alberta
  • Stollery Children's Hospital — Edmonton, Alberta
  • University of Alberta Hospital — Edmonton, Alberta

📞 Contact the Study Coordinator

Phone: (780) 391-7687

Email: zackariah.breckenridge@ahs.ca

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Relapsed Non Hodgkin Lymphoma

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗